))
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
Manage episode 436874438 series 3560282
Conteúdo fornecido por Healio, Adam J. Brown, and MD. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Healio, Adam J. Brown, and MD ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?
- Intro 0:11
- Recap of part 1 & 2 0:28
- In this episode 1:44
- Cyclooxygenase 2 (COX-2) and the rat experiment 3:12
- What do we know about the prostaglandins? And what about COX-2 7:54
- What does prostacyclin do? 10:33
- The first COX-2 inhibitor: VIOXX 10:56
- What is COX-2 doing?: Pfizer and Merck 12:15
- Two more NSAID studies: colon cancer, Alzheimer’s disease and COX-2 inhibitors 18:41
- VIOXX: Why is myocardial infarction risk occurring? 22:34
- Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49
- PRECISION trial 30:25
- Rheum + Boards 37:14
- Thanks for listening 37:32
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Anderson GD, et al. J Clin Invest. 1996;doi:10.1172/JCI118717.
Funk CD, et al. J Cardiovasc Pharmacol. 2007;doi:10.1097/FJC.0b013e318157f72d.
Hennan JK, et al. Circulation. 2001;doi:10.1161/hc3301.092790.
Krumholz HM, et al. BMJ. 2007;doi:10.1136/bmj.39024.487720.68.
Nissen SE, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1611593.
Disclosures: Brown reports no relevant financial disclosures.
84 episódios
Compartilhar
